Orthocell sees four patients benefit from CelGro trial

Company News

by Rachael Jones

Regenerative medicine company Orthocell (ASX:OCC) have seen the first four patients successfully complete participation in the CelGro® nerve regeneration clinical trial.

Following surgery with CelGro®, patients have regained muscle function and/or sensation of affected limbs and have returned to work, sport and activities of daily living.

The patients had previously suffered traumatic peripheral nerve injuries following motor vehicle, sporting and work-related incidents, resulting in complete paralysis, or impaired use of the upper limb.

Shares in Orthocell (ASX:OCC) closed flat at 11.5 cents yesterday.


Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?